Degarelix
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DEGARELIX |
|---|---|
| Type | Drug |
| Aliases | FirmagonДегарелікс |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | GnRH antagonist (LHRH antagonist) |
|---|---|
| Mechanism | Direct GnRH-receptor antagonist — immediate (no flare) suppression of LH/FSH and testosterone within days, vs 2-4 weeks for agonists. Preferred when rapid testosterone suppression is required (e.g., spinal cord compression risk, severe bone pain, hyperviscous metastatic burden). |
| Typical dosing | Loading: 240 mg SC (two 3-mL injections) on day 1; maintenance 80 mg SC monthly. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
First-choice ADT when rapid suppression matters or when tumor flare is unacceptable. Also slightly lower CV-event risk vs LHRH agonists in some meta-analyses.
Used By
No reverse references found in the YAML corpus.